HOME >> BIOLOGY >> NEWS
Breast cancer and hormone therapy -- A looking-glass mirror?

The medical community has been debating for many years whether, and to what extent, postmenopausal hormone therapy (HT) use is associated with a higher risk of breast cancer, says Professor Amos Pines, President of the International Menopause Society. Although it is agreed that long-term HT slightly increases that risk, the definition of long-term use is still unclear, particularly in view of data showing that it may vary significantly by type of HT (estrogen-alone vs. estrogenprogestin, brand of progestin, dosage). A new study from the Kaiser Permanente health plan[1] raises the question whether trends in breast cancer incidence and use of HT over the past 25 years may be directly linked.

The Womens Health Initiative (WHI) trial was a landmark in menopause medicine since it provided information based on the best available study methodology[2]. By adopting its results as the ultimate source of information, many organizations, medical societies and health authorities actually declared that data derived from observations in the postmenopausal population are less valuable. Nevertheless, during the past few months, several studies have used databases on the incidence of breast cancer, on the one hand, and sales of HT on the other hand, in order to suggest a direct link between trends of hormone use and the number of newly diagnosed breast cancer patients. While such information, by itself, is very important and interesting, conclusions must be drawn with great caution. It is tempting to simplify the observed year-by-year figures on HT use and breast cancer incidence and establish a mirror glass equation: the more postmenopausal hormone use, the more breast cancer, and vice versa. But human biology is far too complicated and the pathophysiology of breast cancer is far too complex to adopt such a mechanistic approach, as the authors of those studies and related Editorials rightly say.

The mere fact that the incidence of lung cancer is higher among
'"/>

Contact: Jean Wright
jwright.ims@btopenworld.com
International Menopause Society
24-Jul-2007


Page: 1 2 3

Related biology news :

1. Breast cancer prognosis runs in the family
2. Breast cancer milieu -- Progression, tamoxifen sensitivity, and DNA reversion
3. Is bigger better? Breast surgery linked to boost in self-esteem and sexuality
4. Breast cancer treatment heats up
5. Genesearch Breast Lymph Node assay detects breast cancer metastases with greater sensitivity
6. Breast Cancer Month story tips from Georgetown University Medical Center
7. Breast density helps predict breast cancer risk
8. Breast stem cells have features similar to basal tumors
9. Breast cancer genetics and more -- press release from PLoS Medicine
10. Breast-sparing surgery an option for women with breast cancer gene mutation, U-M-led study finds
11. Breast implants not associated with cancer risk, study reports

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/2/2019)... ... November 01, 2019 , ... Stay on top of current ... device industries. Access to all webinars is free, so be sure to register today ... , Visit http://www.xtalks.com to see our upcoming webinars: , CLINICAL OPERATIONS , ...
(Date:10/30/2019)... Va. (PRWEB) , ... October 30, 2019 , ... ... offering from the Farm Credit Knowledge Center in which participants will learn about ... industry best practice relating to these technologies. , Participants will have the ...
(Date:10/30/2019)... ... October 30, 2019 , ... Amberdata Inc., the ... firms, including Fenbushi Capital, DF Capital, Rising Tide Fund, and HWVP. The ... to further accelerate its position as the leading data provider of institutional-grade blockchain ...
Breaking Biology News(10 mins):
(Date:10/22/2019)... , ... October 22, 2019 , ... ... has announced that its lead program, DBI-001, met its primary safety endpoints, with ... labeled phase 2a clinical trial for the treatment of interdigital tinea pedis (athlete’s ...
(Date:10/17/2019)... ... October 16, 2019 , ... ... easy-to-understand, web-based genetic counseling information, has published a new white paper that explores ... and provides guidance as to how patients and medical providers can be kept ...
(Date:10/10/2019)... Md. (PRWEB) , ... October 09, 2019 , ... ... announced Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a newly-confirmed keynote ... 27–30 October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, a hematologist/oncologist ...
(Date:10/10/2019)... (PRWEB) , ... October 10, 2019 , ... R3 Stem ... The next course is October 18-19th, 2019 in Las Vegas with spots still open. ... He completed training at several Ivy League universities including Cornell, Harvard and Dartmouth. He ...
Breaking Biology Technology:
Cached News: